Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is characterized by the slow accumulation of small, mature B cells and prolymphocytes that typically display the CD5, CD19, CD23 and CD20 markers. CLL/SLL cells suffer spontaneous apoptosis in vitro. However, they are rescued when cultured with follicular dendritic cells, other dendritic cells or with a CD40-ligand (CD154)-expressing fibroblast cell line. Furthermore, it has been demonstrated that CLL/SLL cells Figure 3 Effect of tyrosine kinase inhibitors on tyrosine phosphorylation and survival of cells derived from imatinib-resistant CML patients expressing T315I-mutant BCR-ABL. Three CML patients (a-c) who progressed on imatinib therapy were found to express only T315I-mutant BCR-ABL. Mononuclear cell preparations from each patient were incubated with imatinib (5 mM), dasatinib (0.5 mM) or ON012380 (5 mM) for 4 h before equal protein lysates were subjected to immunoblotting for phosphotyrosine, pY-CrkL and CrkL. Untreated K562R cell lysate was used as a positive control for specific phosphoproteins. Cells incubated for 48 h with inhibitors were stained for markers of apoptosis and analyzed by flow cytometry. Percent survival is based on relative changes in apoptosis in treated vs vehicleonly (control) treated cells. The values represent the average±s.d. of three replicates.
Letters to the Editor are protected from apoptosis by their interaction with nurse-like cells, a subset of blood monocytes described in the spleen of CLL/SLL patients that express vimentin and stromal-derived factor 1 (SDF1), together with high levels of CD14 and CD68. 1 Thus, evidence is accumulating that the defective apoptosis of CLL/SLL B cells can be ascribed not only to intrinsic defects of the neoplastic cells, but also to extrinsic factors in the microenvironment that influence their behavior. 2, 3 CLL/SLL lymph node infiltration has a distinctive characteristic, the presence of pseudofollicles or proliferation centers (PCs), which are more rarely described in the white pulp of the spleen and the bone marrow. PCs are newly formed structures, and have not been described in reactive lymphadenitis or other lymphoproliferative conditions. They contain a pool of proliferating cells that appear as vaguely nodular areas that can be recognized against a monotonous background of small maturelooking lymphocytes because they are clearly visible at low magnification. 4 PCs contain a continuum of small, medium and large cells consisting of prolymphocytes, which are small to medium-sized cells with relatively clumped chromatin and small nucleoli, and paraimmunoblasts, which are larger cells with round to oval nuclei, dispersed chromatin, central eosinophilic nucleoli and slightly basophilic cytoplasm. PCs have been proposed as being the site for B cell receptor signaling, and B cells within PCs have been shown to express IRF4, suggesting that PC morphology may reflect important biological features of this neoplasm. Nevertheless, these anatomical structures are not observed in lymph nodes of the existing CLL/SLL mouse models, which makes it difficult to address their functional relevance.
Previous studies have shown that CLL/SLL cells possess constitutively activated NF-kB, which appears to enhance leukemia cell survival. 5 However, the location and mechanisms that trigger NF-kB activation in CLL/SLL cells are not fully understood. Herein, we describe the cellular composition and organization of PCs and address whether PC cell composition is involved in NF-kB activation. We have taken advantage of the availability of new markers for specific cellular subpopulations present in the lymph node and others related to CD40 signaling and NF-kB activation.
Seventy-two consecutive CLL/SLL cases submitted for diagnosis or for a second opinion to the CNIO pathology laboratory between 2000 and 2007 were analyzed. Criteria for the diagnosis of CLL/SLL were based on WHO recommendations (WHO 2008). The project was supervised by the Ethical Committee of the Instituto de Salud Carlos III. Representative areas containing PCs from 48 formalin-fixed, paraffin-embedded lymph nodes infiltrated by CLL/SLL were studied using Tissue microarrays (TMAs). Twenty-four additional cases of CLL/SLL, including the bone marrow, spleen, skin and breast tissue samples, were analyzed in whole-tissue sections. Antibodies used are shown in Supplementary Table 1. A staining score was recognized for most of the proteins analyzed based on the percentage of positive cells: 0 ¼ 0-5%, 1 ¼ 15-50% and 2 ¼ 50-100%. Thirty-five cases were also studied for IGHV gene rearrangement status, and cytogenetic abnormalities for 11q22, 17p13, 13q14 and trisomy 12 by FISH. 6 The mutational status and frequency of cytogenetic anomalies in this series did not change significantly from previous studies ( Table 1) .
We found PCs in all 72 cases analyzed, except for one bone marrow sample, although their size and number varied. One of the most interesting findings was the presence of specific cellular subpopulations in the PCs, including reactive small T cells, stromal cells and macrophages, in addition to the endothelial cells and B prolymphocytes/paraimmunoblasts ( Figure 1 ).
All PCs showed Ki67 and IRF4 expression by the large B cells, thus confirming the findings of previous studies. Surprisingly, in all cases it was possible to identify that large B cells also displayed nuclear expression of NF-kB subunits, confirming previous suggestions that this pathway is constitutively active in CLL. Nevertheless, only p50, p52 and Rel-B subunits of NF-kB were found in the nucleus of PC prolymphocytes, although in different percentages of cases (Supplementary Table  2 ). This contrasts with the findings in small lymphocytes occupying the inter-PC area, in which no nuclear translocation of NF-kB subunits was identified. P50 was the most conspicuous subunit in the PCs, where it was found in most cases. P50-negative cases expressed either p52 or Rel-B (Supplementary Table 2 ). P50 and p65 are both known to bind to the IRF4 promoter region and induce its transcription, which is in accordance with the observation of IRF4 expression in PCs. Although the p50 subunit forms a dimer with p65 in most cell types and conditions, other subunit complexes are also known to participate in the regulation of cellular processes and tumorigenesis. Recently, nuclear p65 (Rel A) expression has been reported in circulating CLL/SLL. 7 Discrepancies with our study could be related to the different methods used for detecting NF-kB subunits or to the different expression levels of the NF-kB subunits in circulating lymphocytes compared with PCs.
VEGF, PD-1, BAFF, MCL1, CD25, CD40, NF-ATc1, TNF receptor-associated factor (TRAF1) and BIRC5 were also overexpressed exclusively in prolymphocytes. Conversely, CD20, BCL2, TCL1, IgD, IgM, CD38, CD23 and ZAP70 were expressed in both PCs and non-proliferating small B cells of CLL/SLL. No immunoreactivity was found for germinal center (GC) markers (BCL6, GCET1 and CD10) or CD30. NF-kB targets, such as BCL2, MCL1 and BIRC5, which are believed to be essential mediators in survival and apoptosis inhibition of CLL/SLL cells, were also positive in most of our cases (Figure 1 ). These data are consistent with the experimental study of Basso et al., 8 who demonstrated that B cells acquire a specific signature upon CD40 activation that includes IRF4, p50 and TRAF1, all of which are specifically expressed in PCs.
Interestingly, in our series, TRAF1 was found to be positive in both the nucleus and cytoplasm, frequently at the same time. The presence of nuclear TRAF1 expression was confirmed by immunohistochemistry in paraffin-embedded tissues and immunofluorescence in frozen samples. TRAF1 is a member of the TNFR receptor-associated factor 1 family that characteristically lacks the RING domain. It was also found in prolymphocytes of most cases (Figure 1 ). This is especially interesting, since Zapata et al. 9 demonstrated that transgenic mice overexpressing BCL2 and a TRAF2 mutant, which mimics TRAF1 in B lymphocytes, developed a CLL/SLL-like lymphoproliferative disorder. TRAF1 is known to participate in a feedback loop that controls excessive NF-kB signaling, and raised TRAF1 protein levels have been found in several lymphoid malignancies, including CLL/SLL. Strikingly, in our series we observed overexpression of TRAF1 in the nucleus and cytoplasm of B cells within the PCs, a surprising feature that has previously been described in Hodgkin Reed-Sternberg cells. 10 This finding deserves further investigation.
Nuclear staining for NF-ATc1 and BAFF was also noted in prolymphocytes, which is consistent with previous reports on B cell malignancies. 11, 12 NFATc1 can also be activated in response to CD40 or BCR signaling and is active in those cases that are unresponsive to surface Ig ligation. 13 In our series, we observed activated nuclear NFATc1, which can activate BAFF at the transcriptional level, contributing with NF-kB to create a positive feedback loop that favors survival of malignant B cells 14 ( Figure 1 ). These data suggest that BAFF acts autocrinally, promoting survival of prolymphocytes in PCs, as has been shown for circulating CLL/SLL cells.
CD40 stimulation can also induce weak but constant upregulation of PD1 (a type 1 transmembrane protein belonging to the CD28-B7 signaling family of receptors) in CLL/SLL blood cells, a feature that has already been described. 15 VEGF is another important mediator of the antiapoptotic effect of CD40 ligation that is essential for NF-kB activation 16 ( Figure 1) . Furthermore, proteins such as BIRC5 and MCL1, expressed by prolymphocytes inside the PCs, are involved in VEGF-mediated CLL/SLL cell survival.
All these data suggest that B cells within PCs have activated signaling pathways, such as CD40 and BAFF signaling, coupled with the B-cell receptor, that contribute to NF-kB activation. Interestingly, nuclear NF-kB subunits were found in prolymphocytes of PCs of all cases analyzed, indicating that they may Abbreviations: NV, non-valorable, (+), positive, (À), negative. TMA were scanned with the Bliss system (Bacus Laboratories, Lombart, IL, USA) and quantitatively scored on a scale of 0-100 with the TMAscore v.1.0 image analysis software (Bacus Laboratories), which uses Webslide v1.0 (BLI) virtual slides. ZAP70 expression was classified as positive or negative after visual inspection and comparison with the level of expression of reactive T-cells. Cases were divided into two groups with respect to the median value of protein detection in the whole series. IGHV gene analysis was performed using standardized protocols. 6 A sequence was considered mutated when there was o98% homology with the closest germ line V H genes. Standard multi-color probe sets for ATM, p53, 13q14 region and chromosome 12 were hybridized on paraffin-embedded tissue following standard protocols. 6 Tumor samples with 425% of cells with one signal were considered to be subject to genomic loss involving the targeted genomic region. The cut-off value for trisomy was established with the same three normal non-tumor samples. Gain or amplification was defined as the presence (in 45% of tumor cells) of three distinctive signals. Letters to the Editor have a major role in the enhanced survival and proliferation of CLL/SLL cells within lymph nodes (Figure 1) .
Nevertheless, it is believed that neoplastic alterations alone are not sufficient to ensure the survival of CLL/SLL cells.
When compared with the surrounding tissue, it was apparent that PCs contained more T cells (CD3-positive cells), many of which expressed CD40L, as shown by double immunofluorescence (Figure 1) . Moreover, double immunohistochemistry combinations using a large panel of markers for stromal cells and macrophages revealed the presence of at least two populations of macrophages/stromal cells. One subgroup of stromal cells expressed ACTIN/SDF1 and another was positive for STAT1/CD68/CD40 (Figure 1 ). The latter group was considered to be comprised of macrophages and was named STAT1-positive macrophages (STAT1-Ms). The nonmacrophage stromal cells were also occasionally positive for D2-40 and CD23, but not for CD21. No immunoreactivity was found for STAT3, STAT4, CXCL13, CD1a, S-100 protein, desmin or TRAF1 in either group. Electron microscopy studies confirmed our findings and showed the presence of at least these two types of non-lymphoid cells in PCs (Figure 1 ). The relevance of these findings in cases lacking lymph node involvement, or the differences between lymph node and peripheral blood CLL/ SLL cells in the same patients, is still to be investigated. Such research seems likely to improve our understanding of CLL/SLL biology.
In conclusion, the present paper suggests that PCs are the niches where NF-kB activation takes place, leading to the maintenance of CLL/SLL survival, enhancing proliferation and inhibiting apoptosis. It is plausible that the process is triggered by concerted signaling from BCR, CD40 and TNF receptors, with the help of T cells and specific subpopulations of macrophages. However, the relationships between these cell types are still poorly understood and need further exploration by functional studies.
